SCHEMBL2124535

SCHEMBL2124535

CCS(=O)(=O)Nc1ccccc1Nc1nc(Nc2cnn(C)c2)ncc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 3/20 0.56
ALK Q9UM73 6/20 0.56
CDK19 Q9BWU1 4/20 0.52
JAK3 P52333 9/20 0.52
JAK1 P23458 8/20 0.52
JAK2 O60674 4/20 0.50
CDC7 O00311 2/20 0.50
DAPK3 O43293 2/20 0.50
ROCK2 O75116 2/20 0.50
PRKD3 O94806 2/20 0.50
MAP4K4 O95819 2/20 0.50
PAK4 O96013 2/20 0.50
PIM1 P11309 2/20 0.50
PRKACA P17612 2/20 0.50
CDK2 P24941 2/20 0.50
SYK P43405 2/20 0.50
CSNK1A1 P48729 2/20 0.50
CLK2 P49760 2/20 0.50
GSK3A P49840 2/20 0.50
GSK3B P49841 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121008 0.90 GLO1 (0.69) GLO1ALKCDK19JAK3JAK1
SCHEMBL2127160 0.88 JAK2 (0.65) ALKCDK19JAK3JAK1JAK2
SCHEMBL2122169 0.82 GLO1 (0.51) GLO1ALKJAK3JAK2CDC7
SCHEMBL2124254 0.81 GLO1 (0.55) GLO1ALKCDK19JAK3JAK1
SCHEMBL2121349 0.79 GLO1 (0.50) GLO1ALKJAK3JAK2CDC7
SCHEMBL2123175 0.78 GLO1 (0.63) GLO1ALKJAK3JAK1JAK2
SCHEMBL2122267 0.78 ALK (0.78) GLO1ALKCDK19JAK3JAK1
SCHEMBL2123417 0.78 ALK (0.67) GLO1ALKCDK19JAK3JAK1
SCHEMBL2122745 0.76 GLO1 (0.56) GLO1ALKCDK19JAK3JAK1
SCHEMBL10074538 0.76 GLO1 (0.55) GLO1ALKJAK2CDC7GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US claimed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP claimed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO claimed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP disclosed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS ZAP70, JAK3, JAK2 GLO1 3371/4885ALK 233/4885CDK19 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.